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The cellular slime mold Dictyostelium discoideum has an intracellular phosphodiesterase  which specifically 
hydrolyzes cGMP. The enzyme is activated by  low cGMP concentrations, and is involved in  the reduction of 
chemoattractant-mediated  elevations of cGMP levels. The interaction of 20 cGMP derivatives with the activator 
site and with  the catalytic site of the enzyme has been investigated.  Binding of cGMP to the activator site is 
strongly reduced  (more than 80-fold) if  cGMP is no longer able to form a hydrogen bond at N2Hz or OZ’H. 
Modifications  at N7,  C8, 03’  and 0’’ induce  only  a small reduction  of binding affinity. A cyclic phosphate 
structure, as well as a negatively charged  oxygen atom at phosphorus, are essential to obtain activation of the 
enzyme. Substitution of the axial exocyclic oxygen atom by  sulphur is tolerated; modification of the equatorial 
oxygen atom reduces the binding activity of cGMP to the activator site by 90-fold. 
Binding of cGMP to the catalytic site is strongly reduced  if cGMP is modified at NIH, C’O,  Cs and 03’, 
while modifications  at NZHz,  N3, N7,  02’H,  and 05’  have  minor effects. Both exocyclic oxygen atoms are 
important to obtain binding of cGMP to the catalytic site. The results indicate that activation of the enzyme by 
cGMP and hydrolysis  of cGMP occur at different sites of the enzyme. cGMP is recognized at these sites by 
different types of molecular interaction between cGMP and the protein. 
cGMP derivatives  at concentrations which  saturate the  activator site do not  induce  the  same  degree  of 
activation of the enzyme (activation 2.3 -  6.6-fold). The binding affinities of the analogues for the activator site 
and their maximal activation are not correlated. Our results suggest that the enzyme is activated because cGMP 
bound to the activator site stabilizes a state of the enzyme which has a higher affinity for cGMP at the catalytic 
site. 
Cyclic nucleotides have important functions in the cellular 
slime mold Dict-yostelium discoideum. This organism lives in 
the soil where it feeds on bacteria. When the food supply is 
exhausted the single cells aggregate to form a multicellular 
slug, which  finally differentiates into a  fruiting  body.  Cell 
aggregation  is mediated  by chemotaxis to CAMP, which is 
detected by cell surface receptors. Extracellular cAMP induces 
a rapid transient accumulation of intracellular cGMP levels, 
which reach a maximal concentration after about 10 s (for 
reviews see [l -  31). 
D.  discoidewn cells contain two classes of cyclic nucleotide 
phosphodiesterase activity. One class of enzymes hydrolyzes 
cAMP and  cGMP with  similar  rates;  these  enzymes  are 
located extracellularly, intracellularly and on the cell surface 
[4-  61. A second class of enzymes hydrolyzes only cGMP and 
is localized only intracellularly [7 -  91.  Non-specific phospho- 
diesterase is present in large excess over the cCMP-specific 
enzyme. These enzyme activities can be easily separated  by 
concanavalin-A -  Sepharose column chromatography, since 
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all CAMP-hydrolyzing activity binds to the column, while the 
cGMP-specific enzyme passes through the column [8]. 
Mutant cells have been isolated which are totally devoid 
of  the  cGMP-specific  enzyme  [lo,  111.  Transduction  of 
chemotactic signals in these mutant cells indicate that cGMP 
is involved in the chemotactic reaction and that in wild-type 
cells cCMP is degraded mainly by the cCMP-specific enzyme 
[121. 
Detailed  kinetic  studies  have  shown  that  the  cGMP- 
specific enzyme is activated  about threefold  by low cGMP 
concentrations, which is due to a decrease of K,,  while V,,, 
is unaltered. Half-maximal activation occurs at about 0.1 pM 
cGMP; it is a second-order process with a half-life of about 
20 s at 0.1 pM cGMP [13]. The use of cGMP derivatives has 
revealed that the enzyme has two distinct cGMP sites, one for 
activation of the enzyme and another for hydrolysis by the 
enzyme; e.g. cAMP binds to neither site, cIMP binds only to 
the  catalytic  site,  and  8-bromoguanosine  3’,5’-monophos- 
phate binds preferentially to the activator site [S, 141. 
cGMP-stimulated  phosphodiesterases have been observed 
in many organisms and tissues [15-  171. They differ from the 
slime mold enzyme in molecular mass and in cyclic nucleotide 
specificity; the  mammalian  enzyme also hydrolyzes cAMP 
[16, 171. In this report the interaction of 20 cGMP derivatives 180 
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Fig. 1. Structures qfcGcCMP derivatives. RcP in compounds 3 and 4 represents the ribosecyclophosphate moiety. Formulae 15-  18 are partial 
structures of  thc cyclophosphate moiety 
with the activator  site and the catalytic site of  the cGMP- 
specific phosphodiesterase from D.  discoideum is described. 
The results show that the derivatives may have very different 
affinities for both sites. Furthermore, we show that each de- 
rivative  may  activate  the  enzyme  to a  different  extent.  A 
mechanism  on the activation process is proposed,  which is 
based on the differential stabilization of an activated and non- 
activated enzyme species by cGMP derivatives. 
MATERIALS AND METHODS 
Materials 
[8-3H]cAMP  (1.5 TBq/mmol) and [fG3H]cGMP  (0.6 TBq/ 
mmol)  were  purchased  from Amersham  International. [8- 
'HIcIMP  was  synthesized  from  [3H]cAMP by  a  slight 
modification [13] of the method of Casnellie et al. [18]. The 
reversed-phase packing material, pBondapak C1,/Porasil  BI 
35 -75  pm,  was  obtained from Waters;  concanava1in-A- 
Sepharose was  from Pharmacia, and  Dowex  AGlX2 was 
from  Serva.  DEAE-Sepharose  and  snake  venom  (Ophio- 
pkugus hannah) were purchased from Sigma. Compounds 1, 
2, 3, 4,  12, 19 and 20 (see Fig, 1 and Table 1) were obtained 
from Boehringer Mannheim; compounds 6, 7, 8, 10 and 11 
were  generous  gifts  from  Dr  Muhlegger,  Boehringer 
Mannheim  [19]; compound  9  was  kindly  supplied  by  Dr 
Shugar (Polish Academy of Science, Warsaw). Compounds 5 
and 13 were synthesized as described [20, 211.  The synthesis 
of compound 14 will be described elsewhere; the syntheses of 
compounds 15, 16, 17 and 18 are given below. 
Synthesis of  guan  0.7  ine 3',5'-m ono( th  io Jpl~ospha  tes (  PS  ) 
and (PR) isonzers (15  and 16) 
Compounds 15 and 16 (PS) and (PR) isomers respectively 
of  guanosine  3',5'-mono[thio]phosphate,  were  synthesized 
according to the procedure for the synthesis of the analogous 
derivatives of CAMP  [22] with some essential modifications. 
The 2'-OH and 2-NH2  functions of cCMP  were protected by 
isobutyryl  groups  in  a  reaction  of  cGMP  (tri-n-butyl- 
ammonium salt, 0.53 g, 1 mmol) with  isobutyric anhydride 
(3.3 ml,  20 mmol)  and  4-dimethylaminopyridine  (0.25 g, 
2 mmol) in  30 ml dimethylformamide  (reaction  time: 24 h; 
isolation:  flash  chromatography;  yield:  75%).  Then 
N2,02'-diisobutyrylguanosine 3',5'-monophosphate  (0.41 g, 
0.6 mmol)  was  converted  to the  diastereoisomeric  mixture 
of N2,02'-diisobutyrylguanosine  3',5'-anilidophosphates  (PR 
and PS) by means of triphenylphosphine (0.48 g, 1.83 mmol), 
carbon tetrachloride (0.28 g, 1.83 mmol) and aniline (0.34 g, 
3.66 mmol) in pyridine solution (isolation: flash chromatog- 
raphy; yield: 24%). An introduction of ["Nlaniline  and the 
subsequent determination of the 'J?lp-  15N coupling constant 
allowed  assignment  of  the  absolute  configuration  at 
phosphorus  in  these  diostereoisomeric  anilidates  1.f31p-lSN 
= 53.7 Hz for the (PR) isomer and 1J31p-15N  = 39.2 Hz for 
the (PS) isomer. The guanosine  3',5'-mono[thio]phosphates 
(15  and  16)  were  synthesized  from  the  correspondent 
anilidates in stereospecific reaction with sodium hydride and 
carbon disulphide [22]: S31P(D20)  = 54.9 ppm for (PS) isomer 
(15) and 831p(D,O) = 56.6 ppm for (PR) isomer (16). 
Synthesis ofguanosine 3',5'-dinzethylamidophosphates  (PS) 
and (PR) isomers (I  7  and 18) 
N2,02'-Diisobutyrylguanosine  3',5'-monophosphate 
(0.33 g,  0.48 mmol),  obtained from  cGMP and isobutyric 
anhydride, was converted to the diastereoisomeric mixture of 
N2,02'-diisobutyrylguanosine  3',5'-dimethylamidophosphate 
(PR and PS) in the reaction mixture containing 5 ml pyridine, 
triphenylphosphine  (0.39 g, 1.5 mmol), carbon tetrachloride 
(0.23 g, 1.5 mmol) and ["N]dimethylamine  (0.23 g, 3 mmol). 
The (PR) and (PS) isomers were purified  and separated by 
flash  chromatography. The  coupling  constant  is  1J31p-lSN 
= 46.5 Hz for the (PR) isomer  and  1J31p-lsN  = 57 Hz for 
the  (PS)  isomer. After removal of the isobutyryl protecting 
groups  by  means  of  2M NaOH  and  methanol  saturated 
with  ammonia, pure diastereoisomers  17 and  18 were  ob- 
tained  [d31P(CDC13) = 8.3 ppm for (PS) isomer (17), 6l1P(CDCl3) 
= 6.9 ppm for (PR)  isomer (18)]. 
Isolation of' the cCMP-spec@ phosphodiestevase 
D. discoideum NC4H cells were grown as described in [13]. 
Cells were starved in suspension for 2 h. All subsequent steps 
were  carried  out  at 0-4°C.  Cells  were  homogenized  by 
sonication. The homogenate was centrifuged at 23000 x g for 
10 min  and  the  supernatant  at  42000 xg for  1 h.  The 
supernatant (8 ml derived from 8 x 10'  cells) was applied to a 
concanavalin-A -  Sepharose column (160 mm x 16 mm diam- 181 
eter)  and  the  column  was  eluted  with  10 mM  sodium/ 
potassium  phosphate buffer,  pH  7.2. The fractions  eluting 
between  18 ml  and 43 ml were combined  and applied  to a 
DEAE-Sepharose  column  (120 mm x 9 mm  diameter)  at a 
flow rate of 25 ml h-’. Then the column was eluted at a flow 
rate of 16 ml h- ‘ with 50 ml10 mM phosphate buffer pH 7.2, 
followed by 85 ml  50 mM NaCl in the same buffer, and with 
100 ml  of a linear gradient of NaCl (0.05-0.2  M) in buffer. 
Fractions  of  4 ml  were  collected  and  assayed  for 
phosphodiesterase  activity and protein  concentrations. The 
fractions which contained the highest  specific activity were 
combined and used in the experiments. In some experiments 
the enzyme was concentrated using Minicon B15 (Amicon). 
Protein concentrations were determined according to the 
method of Lowry et al. [23]. Each experiment was performed 
with duplicate or triplicate incubations on at least three dif- 
ferent enzyme preparations. 
Plz osplz  odies  f erase assays 
Three assays to quantify the enzymatic hydrolysis of cyclic 
nucleotides have been used. Assay I, which has been used to 
map the activator site, was essentially identical to the proce- 
dure described  in  [8,  131.  Briefly,  the  incubations (200 pI) 
contained 10 nM [3H]cIMP (about 2 kBq), cyclic nucleotides, 
10 mM phosphate buffer pH 7.5, and 150 p1  enzyme. After 
30 min at 22°C the incubation was terminated by boiling the 
samples during 2 min. The product, [3H]5’IMP was converted 
to [3H]inosine by snake venom, and the substrate, [3H]cIMP, 
removed by addition of 1 ml ion-exchanger. After centrifuga- 
tion the radioactivity in the supernatant was determined. 
Assay 11, which has been used to map the catalytic site, is 
based on a separation technique by  reversed-phase chroma- 
tography as described in [24]. Briefly, the incubation (100 pl) 
contained 20 pM [’HIcIMP  (1.5 kBq), cyclic nucleotides, buf- 
fer, and 30 pl  enzyme. The incubation was terminated  after 
60 min at 22°C by the addition of 25 p140 mM H3P04  which 
reduces  the  pH  to  3.0.  Then  125 pl  was  applied  to  small 
reversed-phase  columns, which  were eluted  at atmospheric 
pressure with  1.2 ml  1  % methanol in phosphate buffer  pH 
3.0 (yielding [3H]5’IMP)  followed by  1.2 ml 50% methanol in 
buffer (yielding [3H]cIMP). 
Assay 111,  which has been used to measure the hydrolysis 
of all cGMP derivatives, was essentially identical to a proce- 
dure described previously [25].  Briefly, the incubations (20 pl) 
contained  50 pM  cGMP  or  cCMP  drivative,  10mM 
phosphate buffer, pH 7.2, and 10 p1 enzyme (which was con- 
centrated 50-fold by Minicon B15, Amicon). The reaction was 
terminated after 60 min at 22°C by adding 25 p14 mM H3P04 
which  reduces the  pH to 4.0.  Samples were centrifuged at 
8000 x g for 2 min, and 20 p1 of the supernatant were analyzed 
by  high-performance  liquid  chromatography by  using  the 
anion-exchanger Partisil PXS, 10/25 SAX eluted with 25 mM 
KH2P04,  5% methanol, pH 4.5. 
The accumulation of product was linear with time for all 
assays, provided that not more than 40% of the substrate was 
hydrolysed. 
RESULTS 
Isolation and parrial purification 
qf  ihe cGMP-specqic phosphod~es~er~se 
In a crude homogenate of D.  discoideum cells, CAMP  and 
cGMP are hydrolyzed  at approximately  equal rates,  since 
the nonspecific enzyme, which hydrolyzes  both CAMP and 
cGMP, is  in  large excess over  the  cGMP-specific  enzyme. 
The separation of the cCMP-specific enzyme from the non- 
specific  enzyme  by  concanavalin-A -  Sepharose  column 
chromatography has been described previously [8]. It has been 
shown that the cGMP-specific phosphodiesterase isolated by 
this procedure is activated by low cGMP  concentrations and 
that activation  of the enzyme by  cGMP and hydrolysis  of 
cGMP occur at different sites of the enzyme. 
Both the catalytic activity and the activation property of 
the enzyme were measured during the purification procedure. 
Ammonium  sulphate precipitation  can not be used, due to 
the  loss  of  catalytic  activity;  DEAE-cellulose  column 
chromatography,  which has been used by others to isolate the 
cGMP-specific enzyme from D. discoideum [7,9], is not useful 
in this experiment, since the activation property is largely lost. 
Affinity  chromatography on a  matrix in  which  the  ligand 
8-NH2(CH2)2-S-cGMP  is coupled to CNBr-activated Sepha- 
rose is not successful, because the described method for the 
affinity ligdnd [26] does not yield 8-NH2-(CH2)2-S-cCMP  in 
our hands. Affinity chromatography on a  matrix  in which 
cGMP is immobilized on epoxy-activated Sepharose [I71 can 
not be used, since the cGMP-specific enzyme elutes from the 
column with a wash step containing 10 mM NaCl. This can 
be expected since cGMP is bound to the Sepharose column 
via its 2-amino or 2’-hydroxy groups [17] and both groups are 
required  to obtain binding of cGMP to the activator site of 
the Dictjmteliunz cGMP-specific enzyme [8, 141. 
DEAE-Sepharose  column  chromatography  has  been 
found to be  the only procedure so far to purify the enzyme 
without losing activatability or catalytic properties. cGMP- 
hydrolyzing activity elutes as a single peak at about 0.12 M 
NaCl (Fig. 2). Elution with NaCl up to 0.4 M does not result 
in  another fraction  containing  cCMP-hydrolyzing activity. 
The fractions with  the highest  specific activity  are purified 
about 10-fold compared to the crude homogenate; the yield 
is  about 25%.  The  activation  of  the enzyme by  cGMP is 
completely  preserved  in  this  chromatography  step.  The 
enzyme is stable at 2°C for at least four days, without losing 
catalytic or activating properties. 
Sikrion qf  rGM P  du  ivatives 
cGMP can form several interactions with its surrounding 
medium  (water or protein), such as hydrogen  bonds, ionic 
bonds, and hydrophobic interactions.  The derivatives were 
selected to reduce  or remove  one interaction  potential. A 
possible hydrogen bond is prevented in compound 2 at N2H2, 
in compound 3 at N2H2  and N3, in compound 4 at N2Hz, 
N’H  and C60, in  compound 5  at N’,  in compound 12 at 
02’H,  in  compound 13 at 03’,  and in compound 14 at 0’’ 
(see Fig. 1). The activity of these compounds may reveal the 
involvement of one of the mentioned hydrogen bonds in the 
binding  of cGMP to the protein. Compounds 6-11  are all 
modified  at the %position of cGMP. The activity  of these 
compounds may  provide  information on the  space at this 
position in the binding site of the protein and the preferential 
conformation of the base moiety. Compounds 15-18  have 
stereospecific modifications  at the exocyclic oxygen atoms. 
Their activity may provide information on the stereoselective 
recognition of the phosphate moiety by ionic bonds, covalent 
bonds,  or by  hydrogen  bonds.  Additionally,  in the case of 
CAMP  it has  been shown that antagonists may  be present 
among these derivatives [27 -  321. 182 
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Fig. 2. Purificution of cCMP-stirnulatcid cCMP phosphodiestmzse by DGAG-Sepharose column chromatography. cGMP-specific phosphodi- 
esterase was isolated from 8 x lo8  D.  discaideurn cells by concanavalin-A-  Sepharose and applied to a column of DEAE-Sepharose as described 
in Materials and Methods. Fractions of 4 ml were collected and assayed for phosphodiesterase (PDE) activity at 1 pM cGMP (0)  and for 
protein concentration (0).  The concentration of NaCl is indicated by the dashed line 
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Fig. 3. Activution of  the /iydrolysis qfcZMP  by cGMP derivarives. The hydrolysis of 0.01 pM [3H]cIMP (40000 cpm) by the DEAE-Sepharose- 
purified enzyme was measured in the presence of different concentrations of cCMP (O),  b*cGMP (O),  compound 5 (a),  and compound 15 
(A). (A) Hydrolysis is presented as radioactivity formed after an incubation pcriod of 30 min. The assay blank (850 cpm, assay  1) has been 
subtracted from all  values.  (B) The data from A are transformed  to a linear plot [13]. cpm* is the amount of substrate hydrolyzed  in  thc 
absence of any derivative, and cpm that in the presence of the mentioned cGMP derivatives.  The intercept on the absciwi equals -K:  I, whilc 
the intersection with the ordinate equals (a-1)- ', where a is the maximal-fold activation 
Specificity of  the activutor site 
Previously [I31 it has been shown that cIMP is a good 
substrate of the cGMP-stimulated cGMP-specific phosphodi- 
esterase from D. discoideum, but that it does not activate the 
enzyme. Therefore we used ['HIcIMP  as the substrate of the 
enzyme. 
Activation  of  the  hydrolysis  of  10nM [3H]cIMP  by 
compounds 1 (cGMP),  5,8 and 15  is shown in Fig. 3A. These 
data were then transformed to a plot [I31 shown in  Fig. 3B. 
The intersection  with  the  abscissa  equals  -KL1; K, is  the 
apparent  activation  constant  (concentration  of  derivative 
which induces half-maximal activation). The intersection with 
the ordinate equals (a-1)- I where a is the maximal-fold activa- 
tion. The result with all derivatives are summarized in Table 1. 
It appears that some analogs can activate the enzyme 6.6-fold, 
while others activate only 2.3-fold. 
A few derivatives do not activate the enzyme. This could 
imply that they do not bind to the activator site, or that they 
do bind to the activator site, but are unable to activate (is. 183 
Tdbk I. Properties qf  rhc cGMP derivatives 
K, is the apparent activation constant of the derivative [concentration which induces half-maximal activation of the hydrolysis of [3H]~IMP]. 
a is the maximal-fold activation; data between parentheses mean that the derivatives do  not bind to the activator site. ICjo  is the concentration 
or derivative which induces a 50% inhibition  of the hydrolysis of 20 pM clMP as determincd in Fig. 5. The hydrolysis of all derivatives was 
measured by  HPLC; data are prcscntcd relative to the hydrolysis of cGMP 
Analog  Activator site  Catalytic site 
ICso  hydrolyw 
-________- 
PM 
1. Guanosine 3’,5’-monophosphatc  (cGMP)  0.12  3.8 
2.  Inosine 3’,5’-monophosphate  (cIMP)  2 10  (1) 
3. Xanthine 3’,5’-monophosphate  2  10  (1 1 
4.  Adenosine 3’,5’-monophosphate (CAMP)  2  300  (1) 
5.  7-Dcazaguanosine 3’,5’-monophosphate  0.57  2.3 
6. 8-Aminoguanosine 3’,5’-monophosphate  0.10  5.1 
7.  8-Hydroxyguanosine 3’,5’-monophosphate  1.7  4.1 
8. 8-Bromoguanosine  3’,5’-monophosphate (b’cCMP)  0.07  6.6 
9.  8-Isopropylguanosine  3’,5’-monophosphate  1.55  5.1 
10.  8-Morpholinoguanosine 3’,5’-monophosphate  9.9  3.9 
1  1. 8-Benzylaminoguanosine 3‘,5’-monophosphate  I .72  5.8 
12. 2’-Deoxyguanosine 3’,5’-monophosphate  2 10  (1) 
15. Guanosine 3’,5’-mono[thio]phosphate, (PS) isomer  0.1 1  5.4 
17. Guanosine 3’,5’-monophosphodimethylamidate,  (PS) isomer  2 100  (1) 
18. Guanosine 3’,5’-monophosphodimethylamidate,  (PR) isomer  2 100  (1 1 
19. Guanosine 5’-monophosphate  2 100  (1) 
20.  Guanosinc  2 100  (1) 
1  3.  3’-Deoxy-3’-aminoguanosine 3’5’-monophosphate  2.3  2.3 
14.  5’-Deoxy-S’-aminoguanosine  3’,5’-monophosphate  2.5  2.4 
16. Guanosine 3’,5’-mono[thio]phosphate, (PR) isomer  11  3.2 
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Fig. 4. Inhibition ojthe h’cGMP-induced activotion ofcIMP  hydrolysis 
h,r cGMP derivatives which  du not hind  to the catalytic .de. Phos- 
phodicsterase  activity  was measured  by  assay  I  which  contained 
0.01 pM [3€I]cIMP,  DEAE-Sepharose-purified  enzyme, different con- 
centrations of cGMP-derivatives in the absence (open symbols) or 
presence (closed symbols) of 0.3 pM b’GMP.  The cGMP derivatives 
are compound 6 (A,  A), compound  14 (0,  0)  and compound  17 
(8,  0) 
they  are  full  antagonists).  Discrimination  beween  these 
possibilities  can  be  made  by  investigating  whether  the 
derivatives can  inhibit  the activation  induced  by  bscGMP 
(compound  8). The experiment is shown in Fig. 4 for three 
derivatives. Compound 6 activates the enzyme almost to the 
same extent as bscGMP does. By addition of increasing con- 
centrations  of  compound  6  to  an  incubation  containing 
b8cCMP, an exchange between b8cGMP and derivative 6 will 
occur at the activator site. Because compound 6 and b*cCMP 
activate  the  enzyme to  the  same  extent,  no alteration  of 
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enzyme activity occurs. Compound  14 activates the enzyme 
only twofold. The fivefold activation by bscGMP is reduced 
by  compound 14 to a threefold activation. Thus compound 
14 exchanges with bscGMP at the activator site. Compound 
17 does not activate the enzyme. Since it does not reduce the 
activation by b*cGMP it appears that compound 17 does not 
bind to the activator site. Similar experiments were done with 
compounds 2, 3, 4, 12, 19 and 20 which indicate that none of 
them binds to the activator site. 
Spwificiiy qf  the cntulytic siie 
The interaction of cyclic nucleotide  derivatives with the 
catalytic site of a cCMP-stimulated phosphodiesterase from 
rat liver has been determined  by  detecting the inhibition of 
the hydrolysis of substrate by the completely activated enzyme 
[16]. For the present enzyme this would imply that the enzyme 
is activated  by  bscGMP, and that the inhibition of  the hy- 
drolysis of [3H]cIMP  by the derivatives is measured. However, 
the derivatives activate the enzyme to a different extent. Thus 
the addition of, for instance, cGMP to the incubation mixture 
may result in an exchange with bscGMP at the activator site 
(which reduces the hydrolysis of [3H]cIMP, because cGMP 
does not activate  the enzyme as  strongly as b8cGMP), or 
cGMP may  exchange with  [3H]cIMP at the  catalytic  site 
(which also reduces the hydrolysis of [3H]cIMP). 
The procedure we use to establish the interaction of the 
cGMP derivatives with the catalytic site is shown for cGMP, 
b8cGMP, and compound  12 in  Fig. 5. Enzyme  activity  is 
measured at 20 pM  [3H]cIMP, because activation at higher 
substrate concentrations is small (this is due to the fact that 
V,,,  is not altered by  the derivatives; e.g. bscGMP activates 
the enzyme only 2.5-fold). The data at low analog concentra- 
tions are transformed  to the plot  (Fig. 5, top) from which 184 
the rate of enzymatic hydrolysis of 20 cGMP derivatives by 
a  cGMP-stimulated cGMP-specific phosphodiesterase have 
been measured. 
The activator site 
Binding of cGMP to the activator site is strongly dimin- 
ished  (more than 80-fold) if  a hydrogen  bond at N2H2  or 
02'H  cannot be formed. Binding of cGMP to the activator 
site is diminished  20-fold if  a hydrogen bond at 03'  or 05' 
cannot be formed, while binding is reduced only slightly if a 
putative  hydrogen  bond  at N7 is  impaired.  Some  of  the 
analogs modified at the 8 position bind better to the activator 
site than cGMP, and some of them bind worse. The energy 
contribution of a hydrogen bond to the binding energy of a 
ligand  to a  protein  is  above  10 kJ/mol  1331  which  is  pro- 
portional to a 60-fold reduction of binding affinity. Therefore, 
we tentatively propose that cGMP is bound to the activator 
site via hydrogen bonds at N2H2  and 02'H.  Hydrogen bonds 
at N7, 03'  and 05'  are absent. The involvement of hydrogen 
bonds at N'H,  N3,  and C60  in the binding of cGMP to the 
activator site remains unknown, because analogs specifically 
modified at these atom groups are not available. 
A stereoselective recognition  of the phosphate moiety at 
the  activator site  is  indicated  by  the  data for compounds 
15 -  18; modification of the apical exocyclic oxygen atom by 
sulphur (compound 15) does not change the binding affinity, 
while modification of the equatorial exocyclic oxygen atom 
(compound  16)  reduces  the  binding  affinity  90-fold.  The 
uncharged compounds 17 and 18 do not bind to the activator 
site up to 0.1 mM. The nature of the interaction between the 
phosphorus moiety and the activator site of the enzyme are 
not completely resolved by the present data. A covalent bond, 
as was suggcstcd for other cyclic nucleotide binding proteins 
1341,  seems unlikely, because  compound 15 would  have re- 
duced  affinity, and compound 17 would  not be  inactive. A 
charge-charge interaction  is  possible  if it is directed  to the 
equatorial exocyclic oxygen atom (cf. compounds 15 and 16). 
A similar influence on the biological activity by  sulphur 
substitution  has  been  observed  for  the  correspondent 
cAMP[S] derivatives in Escherichia Cali where the (PR) isomer 
has very high biological activity, while the (PS) isomer has 
only low activity [35]. In this case an H-bond-directed ion pair 
betwecn an arginine in the CAMP-acceptor protein and the 
axial oxygen atom in CAMP  was determined by X-ray analysis 
[36]. 
Recently  it  has  been  shown  that  some  of  the  CAMP 
derivatives analogous to compounds 15 -  18 may have CAMP 
antagonizing activities in several CAMP-dependent reactions 
127-321.  None  of  the  cGMP  derivatives  15-18  are 
antagonists for the present enzyme, since compounds which 
bind to the activator site also activate the enzyme. 
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Fig. 5. Inhibition  of  the hydrolysis OJ' cIMP by  cGMP derivutives. 
Phosphodiesterasc activity was measured by assay I1 which contained 
20 pM [3H]cIMP ( ~40000  cpm), DEAE-Sepharose-purified enzyme 
and different concentrations of cGMP (O),  b*cGMP (0),  and com- 
pound 12 (A).  The assay blank (50 cpm) has been  subtracted from 
all data. Top: the data at low derivative concentrations are trans- 
formed to a plot from which the maximal-fold activation is obtained. 
This value is used in the main figurc to indicate the maximal activity 
(loo%, which  is different  for cach  dcrivativc); then  the derivative 
concentration  yielding  half-maximal inhibition  (ICso)  is calculated 
(indicated by arrows) 
the maximal-fold activation is obtained. With this value the 
activity of the enzyme without inhibition at the catalytic site 
is known for the derivative (loo%, Fig. 5). Then the analog 
concentration which inhibits this value by 50% is called IC50. 
ICSo  values (Table 1) range from 14 pM to concentrations 
above 10 mM. Some derivatives do not inhibit the hydrolysis 
of cIMP at even the highest derivative concentrations (which 
is generally 1 mM); apparently, these derivatives do not bind 
to the catalytic site. 
Degvadution of  cyclic nucleotides 
A second characteristic of the catalytic site, besides the 
binding of a substrate molecule, is the enzymatic conversion 
of the substrate. Degradation of  all cCMP derivatives  was 
measured by high-performance liquid chromatography. Only 
eight  derivatives  were  found  to  be  hydrolyzed;  the  other 
derivatives  were  hydrolyzed  at  least  50-fold  slower  than 
cGMP (see Table 1). 
DISCUSSION 
In  this  report  the  apparent  activation  constant,  the 
maximal-fold activation, the apparent inhibition constant and 
The catalytic site 
cGMP is bound to the catalytic site quite differently from 
its binding to the activator site of the enzyme (Table 1). Bind- 
ing of cGMP to the catalytic site is stronlgy diminished  if 
cGMP is modified at N'H/C60, C8,  03',  and at the exocyclic 
oxygen atoms. Modifications  at N2H2,  N3, N7,  02'H,  and 
05'  have only minor effects on the binding affinity of cGMP 
to  the catalytic  site. Therefore,  we  propose that cGMP is 
bound to the catalytic site via hydrogen bonds at N'H  and/ 185 
"0  'I 
~~~  ~ 
Fig. 6.  Tentative models  qf  the  cGMP-binding  sites  in  the  cGMP- 
sti~nulated  cCMP phosphodiesterase from D. discoideum.  The atom 
or atom groups of cGMP directly involved in a binding interaction 
with the protein are indicated by an arrow 
or C60,  at O",  and possibly at one or both exocyclic oxygen 
atoms. Hydrogen bonds at N'H,,  N3, N7, 02'H,  and 05'  are 
abscnt. Bulky substituents at the 8-position strongly reduce 
the binding affinity of cGMP to the catalytic site. 
Tentative models of  the interaction  of cGMP with  the 
activator site and the catalytic site are shown in Fig. 6. Both 
sites have recognition points in the guanine moiety, the ribose 
cyclophosphate moiety,  and at the exocyclic  oxygen atoms, 
but the atoms which are recognized are different in both sites. 
The guaninc moiety is recognized in the pyrimidine ring, but 
not in the imidazole ring; this may explain why CAMP  is not 
recognized at either site. 
Activation mechanism 
Binding of  cGMP  to  the activator site induces an alteration 
at the catalytic site by which substrate is bound more easily 
(rcduction of Km).  We observed that the extent to which the 
cGMP derivatives activate the enzyme is different for each 
derivative. This may imply that many states of the catalytic 
site with different  K,  values exist; the state depends on the 
molecular structure of the cGMP derivative at the activator 
site. On the other hand, the results are more easily explained 
by the assumption that the catalytic site can exist in only two 
states E and E* with respectively high and low Km. Activation 
of the enzyme may then proceed via the cyclic scheme, 
where A is the activator (cGMP or a cGMP derivative), K is 
the equilibrium constant of E and E* (K = [E]/[E*]), and Kd 
is the dissociation constant of EA. If this activation process 
is a closed thermodynamic system, then p = y. In this scheme 
the extent of activation depends mainly on the values  of K 
and b. p is the difference in affinity of the cGMP derivative 
between the non-activated enzyme species E and the activated 
enzyme species  E*. Since these binding affinities depend on 
the molecular structure of cGMP, p will be different for each 
derivate. 
The model  predicts that a complete range of  activation 
folds can be expected if the ratio of affinities of a derivative 
for  E  and  E*  are  different.  The  term  'efficacy'  used  in 
pharmacology to explain the relationship between  stimulus 
molecule and the maximal response evoked in a living cell is 
demonstrated here in a single molecular entity. 
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